The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Improving sickle cell nephropathy with concurrent GBT1118 & losartan treatment
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, comments on the concurrent administration of GBT1118 & losartan in a mouse model of kidney disease in sickle cell disease (SCD). The model exhibits similar kidney damage to humans, and this combination approach has shown promise in reducing albuminuria and proteinuria, two biomarkers of kidney damage. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Kidney disease is a major morbidity and cause of early mortality in people with sickle cell disease. And so our goal is to try to understand how the kidneys are damaged and develop therapies to treat it. The sickle mouse model has a very similar amount of kidney damage to what we see in people. And so in this model, we tested what is currently recommended, losartan, and added an anti-hemolytic agent, GBT1118, and we wanted to see if the combination can help protect the kidneys in older mice when the kidney damage is already established...
Kidney disease is a major morbidity and cause of early mortality in people with sickle cell disease. And so our goal is to try to understand how the kidneys are damaged and develop therapies to treat it. The sickle mouse model has a very similar amount of kidney damage to what we see in people. And so in this model, we tested what is currently recommended, losartan, and added an anti-hemolytic agent, GBT1118, and we wanted to see if the combination can help protect the kidneys in older mice when the kidney damage is already established. We previously showed that the GBT1118 helps protect early kidney damage. With this combination, we showed that this can actually help reduce both albuminuria and proteinuria, two biomarkers of kidney damage, while together they can actually stabilize hemoglobin concentrations.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
